-
The company plans to introduce Beyfortus, which contains the monoclonal antibody, nirsevimab, in a prefilled injection used for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants
-
Beyfortus is used for the prevention of Respiratory Syncytial Virus (RSV) and Lower Respiratory Tract Disease (LRTD) in newborns and infants.
-
Madeliene Roach, Executive Vice President, Business Operations, Sanofi said in a press conference that over the next two years, this GCC will expand to host up to approximately 2,600 employees, making it the largest of Sanofi's four global hubs.
-
Lupin Atlantis Holdings SA has completed the acquisition of Aarane in Germany and Nalcrom in Canada and the Netherlands, along with the associated trademark rights, from Sanofi, the Mumbai-based drug maker said in a statement.
-
The cash infusion is likely to strengthen the balance sheet of the vaccine maker, whose shares lost more than 98% of their value since the early days of pandemic as it struggled to get its vaccine to the market in a timely manner
-
The company introduced the medication after receiving the marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) earlier last year.
-
MV Ramana, chief executive officer, branded markets (India and emerging markets), Dr. Reddy’s, said the portfolio will give Dr Reddy’s a solid presence in the vaccine segment.
-
Sanofi India's concerned employees will have the opportunity to work at Emcure, it added.
-
Lupin Atlantis Holdings SA, Switzerland, a wholly-owned subsidiary of the company, has signed an asset purchase agreement with Sanofi, a French multinational pharmaceutical and healthcare company, for the purpose, Lupin said in a regulatory filing.
-
Myoril, used to treat muscular pain in conditions like muscular tension has annual sales of Rs. 38 crore according to IQVIA's May 2023 data
-
Sanofi’s India head said his company will look to take advantage of the initial success of the ‘India for India’ plan by enhancing focus on healthcare and pharmaceuticals as essential priorities for the future in the country.
-
The drugmaker is offering voluntary retirement scheme (VRS) to all its employees at two sites near Hyderabad, a spokesperson for Sanofi's India unit told Reuters in an email.
-
The US biotechnology giant offered around $116.5 for each Horizon share, said the person, who asked not to be identified as the information is private. The offer price is at a around 20% premium to Horizon’s closing price of $97.29 on Friday.
-
In a trial involving 13,000 adults, when given as a first dose the vaccine demonstrated an efficacy rate of 64.7% in people with symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.
-
"Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," the firm, which is developing the vaccine jointly with Britain's GSK, said in a statement.
-
The company’s board has accepted the resignation of Rajaram Narayanan, effective from the close of business hours on April 10, 2022, Sanofi India said in a statement.
-
Immuno-oncology firm Amunix is developing cancer therapies based on cytokines -- small proteins that play a role in controlling the immune system -- and T-cells, a type of white blood cell.
-
In a two-stage approach, the phase 3 clinical study will initially investigate the efficacy of the COVID-19 vaccine formulation targeting the original novel coronavirus strain.
-
Sanofi is looking to conduct a part of its 35,000-participant global Phase 3 trial of its COVID-19 vaccine in India.
-
The French drug giant and its British counterpart GlaxoSmithKline surprised investors and customers late last year when they announced a one-year delay to the launch of their joint COVID vaccine, based on a more conventional technology.
-
The study will test the effectiveness of vaccine candidate formulas against the virus that spread from Wuhan, China, and against a variant first seen in South Africa, the pharmaceutical firms said.
-
The vaccine hit a major setback in December, when its developers announced that it did not appear to work well in older adults and that they would have to delay plans to test it in a Phase 3 trial, the crucial test that will assess the vaccine’s effectiveness.
-
Under the agreement announced Monday, Sanofi will handle final manufacturing steps, including filling, inspecting and labeling vaccine vials and packaging them. The deal involves up to 200 million doses of Moderna''s two-shot vaccine.
-
Sanofi and US company Translate Bio are developing the vaccine based on messenger RNA technology.
-
The move comes after the drugmakers in December said their vaccine would be delayed after clinical trials showed an insufficient immune response in older people.
